C. Saffery

发表

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

A. Wotherspoon, D. Cunningham, D. Ferry, 2013, The Lancet. Oncology.

(CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data

M. Gerlinger, D. Koh, C. Braconi, 2020 .

A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).

A. Wotherspoon, D. Cunningham, D. Ferry, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PLATFORM: Planning treatment of oesophago-gastric (OG) cancer—A randomised maintenance therapy trial.

D. Cunningham, F. Thistlethwaite, R. Petty, 2016 .

REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

D. Smith, A. Wotherspoon, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer.

A. Norman, I. Giddings, P. Workman, 2011, Clinical colorectal cancer.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

D. Cunningham, I. Chau, Y. Chua, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data

M. Gerlinger, D. Koh, C. Braconi, 2020, Frontiers in Oncology.

Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data

M. Gerlinger, D. Koh, C. Braconi, 2020, medRxiv.

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

J. Reis-Filho, D. Smith, M. Band, 2013, European journal of cancer.

MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer

D. Tait, K. von Loga, M. Hubank, 2019, Clinical Cancer Research.

1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay

K. von Loga, R. Petty, I. Chau, 2022, Annals of Oncology.

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

M. Gerlinger, K. von Loga, D. Cunningham, 2019, Journal of Immunotherapy for Cancer.

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

T. Hickish, A. Wotherspoon, D. Cunningham, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding

I. Chau, C. Fribbens, C. Peckitt, 2021, Annals of Oncology.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

A. Wotherspoon, D. Cunningham, D. Ferry, 2013, The Lancet. Oncology.

EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers

M. Hubank, A. Wotherspoon, I. Chau, 2019, Annals of Oncology.

P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER

J. Reis-Filho, M. Borad, D. Ryan, 2012 .